Katarab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid reflux and impaired gastric motility. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Katarab-DSR Capsule offers both symptomatic relief and mucosal healing by reducing acid exposure and promoting gastric motility. This combination is indicated for patients requiring both acid suppression and prokinetic therapy. It should be used under medical supervision, with caution in patients with known hypersensitivity to either component or those with underlying cardiac conditions due to Domperidone’s potential to prolong the QT interval. Dosage and duration of therapy should be individualized based on clinical response and tolerability.

Dosage & How to Use